lundi 24 septembre 2018

Onco Actu du 24 septembre 2018

2. Etiologie

Valsartan: review of impurities extended to other sartan medicines [EMA]

2.7 Etiologie - Obésité

Obesity to overtake smoking as top cause of cancer in women [The Telegraph]

How we estimated when obesity might catch smoking as the top cause of cancer [Cancer Research UK]

3.1 Prévention - Tabac

Stoptober: Just 1 in 10 will be smokers in five years' time, says PHE [Cancer Research UK]

3.1.1 Prévention - Tabac - e-cigs

E-cigarettes are almost certainly better than smoking [The Economist]

4.12 Biopsies liquides

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid [Roche]

With new blood test, Roche dives deeper into personal cancer care [Reuters]

4.2 Dép., diag. & prono. - Génome

Raising Awareness of BRCA Mutations [NY Times]

Solving the genome puzzle [The Guardian]

5. Traitements

Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments [NCI]

5.10 Traitements - Essais

How one pharmaceutical company is reinventing the clinical trial [STAT]

FDA proposes stiff fines for failing to report clinical trials [Nature]

Reporting Clinical Trials [In the Pipeline]

5.12.1 Immunothérapies - partenariats

Agenus sells cut of Incyte, Merck milestone streams [FierceBiotech]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Parker collaborator Tessa allies with St. Jude, launches a new T cell program for pediatric brain cancer [EndPoints]

5.12.4 Immunothérapies - Essais

Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain [NCI]

5.13 WCLC

Comprehensive Genomic Profiling Aids in the Identification of Personalized Therapeutic Options [IASLC]

Survey Data from Lung Cancer Alliance Highlights the Unmet Emotional Needs of Long-Term Lung Cancer Survivors [IASLC]

Oncogene-Driven Patient-Caregiver Communities Creating New Paradigm for Non-Small Cell Lung Cancer Research [IASLC]

5.2.1 Pharma - Partenariats

Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts [EndPoints]

5.2.3 Pharma - économie

Y-mAbs Upsizes IPO, Gets $96M to Test Two Pediatric Cancer Drugs [Xconomy]

Ron DePinho raises seed cash for MD Anderson colleague’s work on a ‘Holy Grail molecule’ in cancer, inflammation [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy [AbbVie]

Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma [Exelixis]

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib [Takeda]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018 [EMA]

Takeda lung cancer drug gets European panel nod [Reuters]

5.6 ESMO

ESMO Launches New Patient Guide in Cervical Cancer [ESMO]

6. Lutte contre les cancers

At Joe Biden's Urging, Airbnb, WeWork, And Others Commit To Help Cancer Patients [Forbes]

Biden pushes for progress at cancer summit [Washington Post]

6.1 Observation

Global push to cut deaths from cancer and heart disease wildly off course [The Guardian]

Drugs, Alcohol and Suicide Are Killing So Many Young Americans That the Country’s Average Lifespan Is Falling [Time]

6.7 DMP, Big Data & applis

Dimensions Partners With Reprints Desk To Provide Intelligent Citation References and Journal Article Stats [Dimensions]

6.9 Controverses

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar [NY Times]

Statement from Cochrane's Governing Board [Cochrane]